These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 898119)

  • 1. Clinical and electromyographic examinations on the effect of hydrochloride (Viregyt-K) in the treatment of Parkinson's disease.
    Schubert U; Fischer GJ; Glass J
    Ther Hung; 1977; 25(2):55-63. PubMed ID: 898119
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment with L-dopa and amantadine in Parkinson's disease.
    Pendefunda G; Pollingher B; Stefanache F; Gavril A; Oprisan C; Merling M; Nemteanu E; Ciunru M; Koropitzer I
    Ther Hung; 1975; 23(1):12-6. PubMed ID: 1105871
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current drug treatment of parkinsonism].
    Kistenev BA; Kadykov AS; Pivovarova VM
    Sov Med; 1976 Nov; (11):57-61. PubMed ID: 1006394
    [No Abstract]   [Full Text] [Related]  

  • 4. [Results of treatment with amantadine hydrochloride in Parkinson's syndrome using psychological test study methods. (Preliminary report)].
    Gerstenbrand F; Grünberger J; Oberhummer I
    Wien Med Wochenschr; 1971 May; 121(19):390-7. PubMed ID: 5559920
    [No Abstract]   [Full Text] [Related]  

  • 5. [Results of treatment with amantadine hydrochloride in Parkinson's syndrome using psychological test study methods. (Preliminary report)].
    Gerstenbrand F; Grünberger J; Oberhummer I
    HNO; 1970 Nov; 18(11):390-7. PubMed ID: 5512006
    [No Abstract]   [Full Text] [Related]  

  • 6. [The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
    Shiozawa R; Kase M; Kuroiwa Y; Narabayashi H; Nishitani Y; Ohmoto T; Toyokura Y; Uono K
    No To Shinkei; 1981 Mar; 33(3):301-9. PubMed ID: 7018522
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effectiveness of a combination therapy in the Parkinson syndrome by amantadine hydrochloride and anticholinergic agents].
    Gospavić J; Vidaković Z
    Srp Arh Celok Lek; 1974 Jun; 102(6):447-57. PubMed ID: 4450143
    [No Abstract]   [Full Text] [Related]  

  • 8. Parkinson's disease.
    Lieberman AN
    Compr Ther; 1986 Mar; 12(3):25-9. PubMed ID: 3486090
    [No Abstract]   [Full Text] [Related]  

  • 9. [Amantadine hydrochloride in the treatment of Parkinson's syndrome].
    De la Herrán J; Figuerido JA
    Rev Esp Otoneurooftalmol Neurocir; 1971; 29(167):45-9. PubMed ID: 5091472
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacotherapy: problems and practices.
    Muenter MD
    Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-dopa and amantadine hydrochloride in Parkinson's disease.
    Parkes JD; Zilkha KJ; Knill-Jones RP; Clements PJ; Baxter R
    Int Z Klin Pharmakol Ther Toxikol; 1971 Apr; 4(3):356-60. PubMed ID: 4931417
    [No Abstract]   [Full Text] [Related]  

  • 12. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 13. Controlled trial of amantadine hydrochloride in Parkinson's disease.
    Jorgensen PB; Bergin JD; Haas L; Cuningham JA; Morah DD; Pollock M; Robinson RG; Spears GF
    N Z Med J; 1971 May; 73(468):263-7. PubMed ID: 4932146
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical trial of the therapeutic effect of Amantadine-HCL in Parkinson's Disease].
    Hacohen H; Gurtner B
    Schweiz Med Wochenschr; 1972 Apr; 102(16):583-6. PubMed ID: 5019377
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on the treatment of Parkinson's disease.
    Wirz D
    Conn Med; 1985 Oct; 49(10):633-7. PubMed ID: 3933903
    [No Abstract]   [Full Text] [Related]  

  • 16. Parkinson's disease.
    Morley JB
    Aust Fam Physician; 1977 Jan; 6(1):29-30, 32, 34-5. PubMed ID: 16582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In practice. Parkinson's disease.
    Hill JW
    N Z Med J; 1979 Oct; 90(645):300-4. PubMed ID: 229444
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of Dopaflex and Viregyt-K on gait and postural disturbances of operated and non-operated Parkinsonian patients.
    Boczán G; Borus F; Rózsa L
    Ther Hung; 1975; 23(1):17-20. PubMed ID: 1105872
    [No Abstract]   [Full Text] [Related]  

  • 19. Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease.
    Mastrosimone F; Colucci d'Amato C; De Angelis G; Iaccarino C; Giordano L; Marmo E
    J Med; 1980; 11(5-6):377-83. PubMed ID: 6962824
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacology of Parkinson's disease.
    Burton K; Calne DB
    Neurol Clin; 1984 Aug; 2(3):461-72. PubMed ID: 6152482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.